文献速递临床试验与 GCP流行病学与生物统计

氯吡格雷与阿司匹林用于冠心病二级预防:系统综述与个体患者数据荟萃分析

Clopidogrel versus aspirin for secondary prevention of coronary artery disease: a systematic review and individual patient data meta-analysis.
PubMed 文献 · Lancet · 2025-08-31

该个体患者数据荟萃分析纳入7项随机试验共28982例已确诊冠心病患者,比较氯吡格雷单药与阿司匹林单药。中位随访2.3年,5.5年时氯吡格雷组主要不良心脑血管事件少于阿司匹林组(HR 0.86,95%CI 0.77-0.96,p=0.0082),大出血无差异。作者认为氯吡格雷单药在MACCE预防上优于阿司匹林单药且不增加出血风险。

要点

  • 在已确诊冠心病患者中,氯吡格雷单药较阿司匹林单药降低MACCE风险(HR 0.86,95%CI 0.77-0.96)。
  • 氯吡格雷组与阿司匹林组大出血风险无显著差异(HR 0.94,95%CI 0.74-1.21)。
  • 作者支持在已确诊冠心病患者的二级预防中优先使用氯吡格雷而非阿司匹林。

核心结论

  • 氯吡格雷单药在MACCE预防上优于阿司匹林单药且不增加出血风险,支持在已确诊冠心病患者的二级预防中优先使用氯吡格雷而非阿司匹林。

研究设计与样本

  • 系统检索PubMed、Scopus、Web of Science和Embase从建库至2025年4月12日的随机试验,纳入7项随机试验共28982例患者(氯吡格雷组14507例,阿司匹林组14475例),中位随访2.3年(IQR 1.1-4.0)。
  • 采用半参数共享对数正态脆弱模型(一阶段分析),纳入随机截距解释试验间基线风险差异、随机斜率解释试验间治疗效应差异。
  • 主要疗效终点为心血管死亡、心肌梗死或卒中的复合终点(MACCE),主要安全终点为大出血;研究注册号PROSPERO CRD42025645594。

主要发现

  • 5.5年时氯吡格雷组MACCE少于阿司匹林组(929例事件[2.61/100患者年] vs 1062例事件[2.99/100患者年];HR 0.86,95%CI 0.77-0.96;p=0.0082)。
  • 氯吡格雷组与阿司匹林组大出血无显著差异(256例事件[0.71/100患者年] vs 279例事件[0.77/100患者年];HR 0.94,95%CI 0.74-1.21;p=0.64)。
  • 氯吡格雷组与阿司匹林组死亡率无差异。

临床怎么用

  • 作者认为,已确诊冠心病患者的二级预防可优先使用氯吡格雷而非阿司匹林。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Aspirin monotherapy is recommended indefinitely for patients with established coronary artery disease (CAD). The aim of this individual patient level meta-analysis was to provide a comprehensive evaluation of the comparative efficacy and safety of clopidogrel versus aspirin monotherapy in patients with established CAD, most of whom had undergone percutaneous coronary intervention or had acute coronary syndrome. METHODS: We conducted a systematic search in PubMed, Scopus, Web of Science, and Embase to identify randomised trials published from database inception to April 12, 2025, comparing clopidogrel monotherapy with aspirin monotherapy in patients with established CAD who had discontinued or never started dual antiplatelet therapy. Randomised trials featuring an initial phase of dual antiplatelet therapy were eligible for inclusion in this individual patient data meta-analysis. In the main analysis, we used semi-parametric shared log-normal frailty models (one-stage analysis), including a random intercept to account for differences in the baseline hazard across trials, and a random slope to account for between-trial differences in treatment effects. The primary efficacy endpoint was a composite of cardiovascular death, myocardial infarction, or stroke (major adverse cardiovascular or cerebrovascular events [MACCE]); the primary safety endpoint was major bleeding. This study is registered with PROSPERO (CRD42025645594). FINDINGS: Seven randomised trials including 28 982 patients (14 507 assigned to clopidogrel; 14 475 assigned to aspirin) with a median follow-up of 2·3 years (IQR 1·1-4·0) were eligible and included. At 5·5 years, MACCE was less common in patients assigned to clopidogrel than in patients assigned to aspirin (929 events [2·61 per 100 patient-years] vs 1062 events [2·99 per 100 patient-years]; hazard ratio 0·86 [95% CI 0·77-0·96]; p=0·0082). Mortality and major bleeding (256 events [0·71 per 100 patient-years] with clopidogrel vs 279 events [0·77 per 100 patient-years] with aspirin; 0·94 [0·74-1·21]; p=0·64) did not differ. INTERPRETATION: These findings add to the evidence that clopidogrel monotherapy is superior to aspirin monotherapy for MACCE prevention with no increase in the risk of bleeding, and support the preferential use of clopidogrel over aspirin for secondary prevention in patients with established CAD. FUNDING: Cardiocentro Ticino Institute, Ente Ospedaliero Cantonale, Switzerland.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Valgimigli M, Choi KH, Giacoppo D, et al. Clopidogrel versus aspirin for secondary prevention of coronary artery disease: a systematic review and individual patient data meta-analysis. Lancet. 2025. PMID: 40902613. doi:10.1016/S0140-6736(25)01562-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。